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Abstract
Several naturally occurring phytohormones have shown enormous potential in the prevention and
treatment of several cancers. Strigolactones (SLs) are a novel class of plant hormones produced in
roots and regulate new above ground shoot branching, by inhibiting self-renewal of
undifferentiated meristem cells. Here we study the effects of six synthetic strigolactone analogues
on breast cancer cell lines growth and survival. We show that Strigolactone analogues are able to
inhibit proliferation and induce apoptosis of breast cancer cells but to a much lesser extent ‘non-
cancer’ lines. Given the therapeutic problem of cancer recurrence which is hypothesized to be due
to drug resistant cancer stem cells, we also tested the ability of Strigolactone analogues to inhibit
the growth of mammosphere cultures that are typically enriched with cancer stem-like cells. We
show that Strigolactones are potent inhibitors of self-renewal and survival of breast cancer cell
lines grown as mammospheres and even a short exposure leads to irreversible effects on
mammosphere dissociation and cell death. Immunoblot analysis revealed that SLs analogues
induce activation of the stress response mediated by both P38 and JNK1/2 MAPK modules and
inhibits PI3K/AKT activation. Taken together this study indicates that Strigolactones may be
promising anticancer agents whose activities may be achieved through modulation of stress and
survival signaling pathways.
Keywords
Plant hormone; Strigolactone; GR24; Breast cancer; Apoptosis; Proliferation; Mammosphere;
Cancer stem cell; p38 MAPK; JNK1/2
Correspondence and Requests for materials should be addressed to: Ronit I. Yarden, Department of Human Science, Georgetown
University, St. Mary's Hall Rm 260, Washington DC 20007. riy2@georgetown.edu Tel: 202-687-6872, Fax: 202-687-5553.
The authors declare that there is no conflict on interests.
NIH Public Access
Author Manuscript
Breast Cancer Res Treat. Author manuscript; available in PMC 2013 July 09.
Published in final edited form as:














Breast cancer continues to be the major cause of cancer related deaths in North American
women and other western countries, with an estimated 1.38 million new cancer cases
diagnosed worldwide [1]. Whilst there has been a small decline in breast cancer related
deaths in the past decade, it continues to be the leading cause of cancer related death in
women.
An established history exists for plant derived compounds as effective anti-cancer agents
[2]. Approximately 25% of drugs used in the last 20 years are derived directly from plants.
Vincristine, Irinotecan, Taxanes and Camptothecins are all examples of plant-derived anti-
cancer compounds. More recently a number of phytohormones have been assessed for their
ability to inhibit the growth and survival of human cancer cell lines. Cytokinins are
important phytohormones that regulate plant cell division and exhibit different inhibitory
activities towards cancer cells [3-6]. Methyl Jasmonate (MJ) is a ubiquitous plant stress
hormone belonging to the jasmonate family. MJ has been reported by numerous groups to
induce apoptosis in cell lines derived from various cancer types including breast, prostate,
lung, and bladder cancer [7]. MJ's mechanism of action involves disruption of Hexokinase
function, resulting in severe ATP depletion and mitochondrial perturbation. The cytotoxic
effects of MJ are dependent of glucose availability and involve modulation of AKT
activation and generation of ROS [8-10]. Brassinosteroids (BRs) are plant steroids which
regulate a number of plant processes including growth, differentiation, senescence and
disease resistance. BRs have been isolated from seeds, fruits, leaves, galls and pollen. In
cancer cell lines, BRs regulate Cyclin D1 and cyclin -E levels causing G1 arrest and
apoptosis [11,12].
Strigolactones (SLs) are a novel class of phytohormones, so named because they contain
lactone groups and were first identified as inducers of seed germination of the root parasitic
plant, Striga spp. [13]. Strigolactones exert positive and negative regulation as they
promotes branching of the symbiotic Arbuscular Mycorrhizal (AM) Fungi [14], induce
primordial root formation [15] and inhibit shoot branching by controlling axillary meristem
cells growth [16-18]. Meristem cells or root primordial cells are undifferentiated stem cells
which can produce lateral organs in response to endogenous and environmental cues, while
simultaneously maintaining a central pool of pluripotent stem cells [19]. Interestingly, it was
shown that Strigolactones cause meristem cell cycle arrest and atrophy mainly by inhibiting
cyclin B transcription ([20] and unpublished data). Currently more than ten natural SL exist
and a number of synthetic analogues have been synthesized and used in plant studies
[21-23]. Here we sought to examine whether SLs analogues have an inhibitory effect on
human breast cancer cells, and cancer stem-like cells growth and survival. We show for the
first time that SLs analogues can inhibit cancer cell proliferation and induce apoptosis (in
the low micromolar range). We show that SLs analogues are potent inhibitors of
mammosphere formation and cancer stem-like cell survival. In addition, SLs analogues
inhibited hormone responsive and hormone independent breast cancer cell lines.
Immunoblot analysis revealed that SLs analogues activated the stress induced MAPKs, P38
and JNK1/2 and inhibited PDK1 and AKT. Taken together this study indicates that SLs may




Cells were grown at 37 °C in a humidified 5% CO2-95% air atmosphere. MCF-7, T47D,
MDA-MB-231, MDA-436 and BJ fibroblasts (ATCC, Manassas) were maintained in
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DMEM supplemented with 10% Fetal Bovine Serum (FBS). MCF-10A were maintained in
DMEM supplemented with 5% horse serum (Atlanta Biologicals), 20ng/ml epidermal
growth factor (EGF) (Sigma), 10μg/ml insulin (Sigma) and 500ng/ml hydrocortisone
(Sigma).
Mammosphere Growth
Adherent cells were gently trypsinized, (0.05% trypsin/EDTA) washed 2× in PBS and
filtered through a 40μM cell sieve to obtain a single cell suspensions. MCF7 Cells were
diluted to a concentration of 10,000 cell/mL in serum-free phenol-red free MEBM (MEGM
Bulletkit, Lonza) supplemented with 5 μg/ml bovine insulin, 20 ng/ml recombinant
epidermal growth factor, 20 ng/ml basic fibroblast growth factor (Gibco), 1× B27
supplement, 0.5μg/ml hydrocortisone as previously described [24]. For MDA-MB-231
mammosphere cultures serum-free phenol red-free CnT-27 medium with growth additives
(CellnTEC Advanced cell systems, Bern, Switzerland) was used as previously described
[25]. 0.1 mL was seeded per well of a Ultralow attachment 96 well plates. The following
day the indicated doses of GR-24 (ppm) or vehicle alone (0.6% acetone f/c) were added.
Media was replenished every 3-4 days. Self-renewal capacity of the mammospheres was
determined by re-plating and producing further generations of mammospheres. Secondary
mammospheres were cultivated by dissociation (trpsinization with gently vortexing) of
10-14 day old primary mammospheres. Single cell suspensions were obtained as described
above.
Strigolactone treatments
SLs analogues were solubilized in Acetone (Sigma) at stock concentrations of 1666.67
(GR24, MEB55, ST362, EGO9C) and 7500ppm (EGO5, ST357). Cells were treated at the
indicated doses by diluting the hormone to the required highest concentration in the
appropriate culture medium.
Crystal Violet Growth Assays
Cells were seeded at 1500 (MDA-MB-231, MDA-MB-436 and BJ fibroblasts) or 4000 cells
per well of 96 well plates. The following day media was replaced with phenol-free DMEM
supplemented with 10% charcoal-stripped FBS and the indicated doses of GR24,
Strigolactone analogues or vehicle (acetone) alone as control. At the indicated time points,
individual plates were fixed and stained with crystal violet solution (0.5% crystal violet and
25% methanol) for 15 mins, washed several times in distilled water and plates air dried
overnight. Sodium citrate solution (0.1M) was used to solubilize bound crystal violet and
optimal densities were measured at 560nm (Glomax® -Multi Detection plate reader,
Promega).
XTT Viability Assay
Cells were seeded into a 96 well plates at 1500 cells per well (MCF10, MDA-MB-231,
MDA-MB-436) or 4000 cells (MCF-7) per well in triplicate in normal growing media. The
following day media was replaced with phenol-free DMEM supplemented with 10%
charcoal stripped FBS and the indicated final concentrations of Strigolactone analogue or
vehicle (acetone) alone. Cells were incubated for 3 days, at which time XTT (2, 3,-bis(2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium inner salt)
reduction was used to quantify viability according to manufacturer's instruction (ATCC).
Cells were incubated with XTT reagent for 2-3 hours at 37 °C in a humidified 5% CO2-95%
air atmosphere. Absorbance was recorded by a photometer SPEKTRAFluor Plus, Tecan
(Salzburg, Austria) at 450 nm with 750 nm of reference wavelength. Cell survival was
estimated from the equation: % cell survival = 100 × (At-Ac), where At and Ac are the
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absorbencies (450nm) of the XTT colorimetric reaction (ATCC) in treated and control
cultures respectively minus non-specific absorption measured at 750nm. Absorbance of
medium alone was also deducted from specific readings.
Cell Cycle Analysis
DNA content was assessed by flow cytometry. Cells were seeded at densities of 1.5 × 105
cells (MDA-MB-231, MDA-MB-436) or 4 ×105 cells (MCF-7) per well in in 6-well plate
culture dishes. The following day, the media was replaced with phenol-free DMEM
supplemented with 10% charcoal-stripped FBS with the indicated concentrations of SLs
analogues or vehicle alone (acetone). After 48 h, cells were washed twice with 1 × PBS (pH
7.4), centrifuged at 360g for 10 min at 4°C, and fixed in chilled ethanol (70%; v/v in PBS)
with gentle vortex mixing. To determine their DNA contents, the cells were stained with 40
μg/ml propidium iodide (PI) and analyzed using a FACSCalibur flow cytometer and
analyzed using CellQuest analysis software (Becton Dickinson, San Jose, CA).
Aldeflour Expression
MCF-7 mammospheres were trypsinized, gently vortexed and passed through a 40uM cell
filter to produce single cell suspensions. Cells (5×105) were washed and resuspended in
growth media (Lonza). To identify the Aldefluor-stained cell population with ALDH1
enzymatic activity, the Aldefluor kit (Stem Cell Technologies), which is designed for
optimal identification and isolation of stem cells through specific interaction with human
ALDH1 was used. Briefly, cells were suspended in Aldefluor assay buffer containing
uncharged ALDH1-substrate, BODIPY-aminoacetaldehyde (BAAA), and incubated for 45
min at 37°C, with gently vortexing every 15 mins. BAAA is taken up by living cells through
passive diffusion and then converted by intracellular ALDH into a negatively charged
reaction product BODIPY-aminoacetate, which is retained inside cells expressing high
levels of ALDH1, causing the cells to become brightly fluorescent. Fluorescent ALDH1-
expressing cells were detected in the green fluorescence channel (520-540 nm) of a
FACScan instrument (BD Biosciences). A set of cells were stained using the identical
conditions with the specific ALDH inhibitor, diethylaminobenzaldehyde (DEAB), to serve
as a negative control for the experiment. Propidium iodide (Sigma) fluorescence was
detected using the orange fluorescence channel. Cells incubated with BAAA and DEAB
were used to establish the baseline fluorescence of cells and ALDH1-positive fraction. Data
were analyzed by using Cell Quest software (BD Biosciences).
Immuno-Blotting
Cell lysates were prepared using a lysis buffer containing: 50 mM Tris-HCl (pH 7.5), 125
mM NaCl, 0.5% NP-40, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM EDTA, 50 mM
NaF, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM sodium β-
glycerophosphate, 1 mM PMSF, and a protease inhibitor cocktail (Roche Molecular
Biochemicals) and cleared by centrifugation. Protein concentration was determined using
the BCA Protein Assay (Pierce), and 20–50 μg of lysate were separated in a 10 or 12%
SDS-PAGE gel. After wet transfer, membranes were blocked for 30 min at room
temperature in 5% BSA (Sigma) in Tris-buffered saline containing 0.1% Tween-20. Primary
antibody was incubated for either 1.5 hr at room temperature or overnight at 4°C. Secondary
antibody was incubated for 45 min at room temperature, and proteins were visualized with
West Pico Stable (Pierce). All antibodies were used at 1:1000 dilution unless otherwise
stated. pT308AKT, AKT, pT180/Y182 P38MAPK, P38MAPK, pT202/Y204 ERK1/2,
ERK1, pT183/Y185 pJNK1/2, pT71ATF2, pT581 MSK1, pT334 MAPKAPK, pS82 HSP27
(Cell Signaling Technology, Danvers, MA), α-tubulin (Biomarkers, 1:50,000) and
horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG (1:5,000, Pierce).
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Results are presented as Average ± SD of replicate analyses and are either representative of,
or inclusive of at least two independent experiments. Statistical analyses were performed
using student's t-test (2-tailed, paired) versus vehicle controls and regarded as being
significant when P < 0.05 (*). Higher powers is significance (p<0.01, p<0.001) are also
employed and indicated in each figure legend. IC50 doses for SLs were calculated by
interpolation of the sigmoidal dose response curves (Graphpad Prism 4.0 software). Briefly
linear regression was performed between relevant y-axis data points and interpolation
calculated for x-axis unknowns.
Results
GR-24 inhibits the growth of human breast cancer cell lines
The effect of GR-24 (Supplementary Fig S1) on long-term cancer cell line growth was
assessed by crystal violet assay. MCF-7 (estrogen receptor positive (ER+), tumorigenic,
non-metastatic), MDA-MB-231, MDA-MB-436 (ER negative (-), metastatic) and BJ
fibroblasts (normal, non-neoplastic line) were treated with GR-24 at a dose range of 0.5 to
10ppm (1.65-33μM). Growth was monitored for up to 10 days. Concentrations of 2.5-5ppm
of GR-24 resulted in a significant reduction in growth compared to vehicle treated controls
in MCF-7, MDA-MB-231 and MDA-MB-436. BJ fibroblasts showed no significant
reduction in growth over this time period (Fig 1A). A small reduction was observed at the
highest concentration (10 ppm), however this was minor when compared to the growth
inhibition achieved by the same concentration of GR-24 in MCF7 and MDA-MB-231 cells.
To determine the concentration of GR-24 at which 50% of long-term proliferation was
inhibited (IC50) after 7days, optical densities at day 7 were plotted as a percentage of vehicle
controls (Fig 1B) and concentrations were calculated by interpolation. IC50 concentrations
for MDA-MB-436, MDA-MB-231 and MCF-7 cells were 5.2ppm (17.2μM), 5.7ppm
(18.8μM) and 5.7ppm (18.8μM) respectively (Fig 1B).
GR-24 induces G2/M-arrest and apoptosis
To investigate the effect of GR-24 on cell cycle progression, DNA content analyses were
carried out by propidium iodide staining using flow cytometry. MCF-7, MDA-MB-231 and
MDA-MB-436 cells were treated with 10, 5 and 0.5ppm concentrations of GR-24 for 48
hours and the non tumorigenic breast cell line MCF10A was used as a control. GR-24
treatment causes a dose dependent increase in the percentage of cells in G2/M phase and a
concomitant decrease in the percentage of cells in G1 phase in all tumorigenic cell lines but
no change was observed in the cell cycle distribution of MCF10A cells upon GR-24
treatment (Fig 2A). At higher concentrations (10ppm), GR-24 caused an increase in the sub-
G1/apoptotic fraction of MDA-MB-231 (4.6 fold) and MDA-MB-436 cells (3.4 fold)
compared to vehicle controls, indicating increased apoptosis. MCF-7 cells showed no
change in the subG1 fraction at 10ppm (Fig 2A).
GR-24 inhibits the growth and reduces viability of breast cancer stem–like cell enriched
mammosphere cultures
Tumor Initiating Cells (TICs) or Cancer Stem Cells (CSCs) are intrinsically resistant to
conventional chemo- and radiation therapies [26]. These cells are able to regenerate the
cellular components of the original tumor eradicated by such treatments, and ultimately lead
to recurrence. The ability to target this cell population is important to develop effective
treatment regimes. Mammosphere culture has been used widely for the enrichment of breast
CSCs. MCF-7 cells can be propagated as ‘mammospheres’ under non-adherent, serum-free
growing conditions [27,28]. To determine if GR-24 could inhibit MCF-7 mammosphere
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formation, MCF-7 cells were grown as mammospheres in the presence or absence of GR-24
(Fig 3A). Mammosphere formation was completely inhibited in the presence of 2.5 –5ppm
of GR-24, and severely attenuated at 1ppm, (p<0.01), 5 fold below the concentration
required to inhibit monolayer growth (Fig 1). At 0.5ppm concentrations, growth was
inhibited to a lesser degree however mammospheres were often smaller (<50uM) than
vehicle treated controls (p<0.05). Similar results were obtained when secondary MCF-7
mammospheres were grown in the presence of GR-24 (Fig 3B). To assess the generality in
mammosphere growth inhibition by GR-24, another breast cancer cells line, MDA-MB-231,
was tested (Fig 3C). At 5ppm, GR-24 completely blocked MDA-MB-231 mammosphere
formation. At 2.5ppm, mammopheres growth was severely attenuated, with mammospheres
being substantially smaller (<50uM) compared to vehicle control groups. Importantly, the
concentrations of GR-24 necessary to block MCF-7 and MDA-MB-231 mammosphere
formation were 5.7 and 2.7 fold lower respectively than the IC50 doses for monolayer
growth. Mammospheres therefore exhibit a greater sensitivity to the growth inhibitory
effects of GR-24 versus monolayer culture. This is an interesting finding since
mammosphere cultures reportedly are enriched with TICs and those have been shown to be
inherently resistant to chemotherapy [29,30].
Effect of GR-24 on mammosphere viability and stem cells marker expression
Mammosphere viability was assessed by XTT assay (ATCC). At 5ppm, GR-24 reduced
viability by approximately 80% (98.4%± 3.4 to 16.4%± 4.6) (Fig 4A). Interestingly at
2.5ppm where mammosphere formation is completely inhibited, viability remains at 68.6%
±12.4, suggesting that either timing of inhibition is critical or that apoptotic cell death
cannot account solely for inhibition of mammosphere formation at this concentration. To
further investigate GR-24 induced inhibition of mammosphere formation, the expression of
breast stem cells markers were examined.
Aldehyde Dehydrogenase (ALDH1) has been shown to be a functional marker in the
isolation of TICs in many cancer types [31,32] and MCF-7 TICs can be selected on the basis
of their ALDH activity in combination with other surface markers [33]. ALDH activity was
enriched in primary mammosphere relative to adherent culture and secondary mammosphere
culture reached further enrichment (Fig 3B). GR-24 treatment of primary mammospheres
reduced ALDH activity from 6% to 2%. This data suggests that GR-24 is a potent inhibitor
of mammosphere formation and down regulation of ALDH by GR-24 may account for this
activity.
Strigolactone Analogues are effective growth inhibitors of breast cancer cell lines
An additional five synthetic strigolactone (SL) analogues were obtained (Supplementary Fig
S1) and tested for their ability to inhibit the growth of MCF-7 and MDA-MB-231 cells.
MCF-10A cells were included as an example of a non-tumorigenic line. XTT viability
assays were carried out in the presence of the indicated doses of SLs following 3 days of
treatment. Resulting differences in absorbance readings following SL treatment reflect
changes in proliferation and cell survival (Fig 5). IC50 concentrations are indicated (Table
1). Cell lines exhibited substantial variation in their response to each SL analogue, however
all cancer cell lines were growth inhibited by SL treatment. ST362 and MEB55 were the
most potent SLs. IC50 concentrations of ST362 started as low as 2.9ppm (MDA-MB-231)
and for MEB55, as low as 3.9ppm (MDA-MB-231). The non-tumor cell line, MCF10A, was
resistant to the effects of SL treatment up to 15ppm concentrations, with the exception of
ST362, which caused a 20% reduction in viability between day 10 and 14. EGO9C was the
least effective SL analogue in all cell lines tested (IC50 >10-15ppm). ST357 was a potent
growth inhibitor of MDA-MB-231 (IC50=5.0ppm) cells. Some cell lines exhibited increased
XTT absorbance at lower dose concentrations. Vehicle volumes in controls were matched
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with those in the highest dose only and total vehicle volumes were not matched for lower
doses. Sensitivity to vehicle levels probably accounts for the suppressed viability observed
in controls in relation to the lower doses in some cell lines.
To assess SL stability in aqueous solution, each SL was diluted to the desired concentration
in media and stored at 4°C for 3 days, at which time the SL containing media was overlayed
onto cells. After 3 days growth and viability was assessed (XTT) and results compared to
cells treated with freshly diluted SL (Supplementary Fig S2). All SLs retained similar levels
of activity over this time period, with the exception of EG5 which completely failed to
inhibit MCF-7 growth. For this reason all SLs were diluted fresh from acetone stocks into
media to desired concentrations and overlayed onto cells within 1 hour. Where necessary,
media was refreshed every 3 days.
Strigolactone Analogues inhibit cell cycle progression and induce apoptosis
Here we previously showed that GR-24 treatment caused an increase in the percentage of
MCF-7 and MDA-MB-231 cells in G2/M-phase and apoptosis in MDA-MB-231 and MDA-
MB-436 cells. To determine whether these additional SL analogues also induced a similar
mechanism of growth inhibition, cell cycle analysis was carried out. Results show a dose
dependent increase in the percentage of MDA-231 and MCF7 cells in G2/M phase (Fig 6).
At concentrations 25% above the IC50/72h, there was evidence of increased apoptosis in
MDA-MB-231 cells with increased percentages of cells in the subG1 fraction. MCF-7 cells
were less sensitive to the effects of SLs at the doses tested. BJ fibroblasts were not sensitive
to the effects of SLs at the doses tests (Table 2). Hoechst staining was used to analyze
changes in the nucleus. ST362 treatment at 5-10 ppm resulted in increased nuclear
condensation and fragmentation changes indicative of apoptosis (Fig 7A). To determine if
continual SL exposure is required for growth inhibition and reduced cell survival, MDA-
MB-231 cells were treated with either ST362 or MEB55 at 5ppm and 10ppm for 2, 4 and 24
hours. At each time point the SL was removed and media replaced with fresh growth media.
After a total of 24 hours an XTT assay was carried out (Fig 7B). A significant decrease in
viability was induced as early as 4 hours of SL treatment (p<0.01). No changes in cell
viability were observed after 2 hours exposure. Continual exposure (24h) to each SL
induced a greater reduction in cell viability (p<0.001) compared to 4 hours exposure. These
results indicate that SL analogues induce non-reversible and time dependent decreases in
cell viability.
MCF-7 Mammosphere growth is inhibited by Strigolactone treatment
Given the similar effects the other SL analogues had on breast cancer cell line growth
compared to GR-24, we anticipated that the SLs would also have similar effects on MCF-7
primary mammosphere formation. As expected, all five SLs were able to completely block
mammosphere formation at concentrations of 5ppm and above (Fig 8A). ST362 and MEB55
were also able to block mammosphere growth at 2.5ppm. ST357 showed a significant
reduction in mammosphere growth at 2.5ppm (p<0.01). ST357, ST362 and MEB55 also
significantly inhibited mammosphere formation at 1ppm (p<0.01). This data is consistent
with these SLs being the most potent inhibitors of MCF-7 monolayer growth (Fig 5, Table
1). Like GR-24, the doses required to inhibit mammosphere formation were lower than that
required to inhibit proliferation in monolayer cultures (5 fold lower; ST362 and MEB55, 3
fold lower; ST357). To determine if the sensitivity to SLs treatments was specific to
mammosphere formation or whether it extended to the integrity and survival of mature
mammospheres, MCF-7 mammospheres were grown in the absence of SLs and after 7 days
(or once mammospheres had reached a mean diameter of over 100uM), SLs were added to
the growth media (Fig 8) at the indicated doses. Mammospheres were monitored visually
after 24 and 48hours. No changes were observed following 24 hours of SLs treatment (data
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not shown). After 48 hours, mammospheres treated with ST362, ST357 and MEB55, at
doses of 5 and 2.5ppm, exhibited a looser morphology and appeared to be dissociating.
Representative images of mammospheres treated with 5ppm concentrations are shown (Fig
9A). Mammospheres treated with EGO9C showed a less dramatic morphological change,
which correlates with the reduced potency of this SL to inhibit mammosphere formation
(Fig 9). Following 5 days of treatment, mammosphere numbers (≥100μM) were counted and
data presented as percentage of vehicle treated control (Fig 9B). At 5ppm concentrations
EGO5, EGO9C, ST357, ST362 and MEBB55 reduced mammosphere numbers from
86.7±6.8 (vehicle control) to 23±5, 38±6.2, 6±2, 8.3±3.5 and 9.3±1.5% respectively. At
2.5ppm concentrations, mammosphere numbers were reduced to 35±6.9 (EGO5), 52±12.3
(EGO9C), 22±8.5 (ST357), 6±1.7(ST362) and 20.7±8.6 (MEB55). As expected, these
results correlate closely with the analogues ability to inhibit mammosphere formation (Fig
8). XTT viability assays were also carried out on dissociated mammospheres.
Strigolactone analogues activate stress-activated MAPKs and inhibit survival signaling
To investigate the signaling mechanisms elicited by SLs in cancer cells MDA-MB-231 cells
were treated with SL analogues for 1, 4 or 8 hours and lysates were analyzed by immuno-
blotting. The family of MAPK enzymes plays a pivotal role in cell growth, survival and
cellular stress responses. The best characterized MAPKs fall into three families, the mitogen
activated extracellular signal regulated kinases (ERK1/2) which are activated in response to
positive proliferation signals, c-Jun amino (N)-terminal kinases (JNK1/2/3) and p38
isoforms (p38α, β, γ, δ), both are activated by environmental stress stimuli such as DNA
damage, UV irradiation and inflammatory cytokines. There was no change in the total
protein levels of ERK1/2 (Fig 10A) although some dose-independent changes were noted in
pERK1/2. Interestingly, ST362 induced a time dependent and dose dependent increase in
pP38 levels which was first evident after 4 hours of SL exposure. At 4 hours and 8 hours,
pP38 levels increased 5 fold and 13 fold respectively following ST362 treatment compared
to vehicle controls (Fig 10B). To determine if pP38 levels translated into activation of down-
steam signaling, nuclear P38 substrates, Activating Transcription Factor 2 (ATF2), which
belongs to the ATF/cAMP response element-binding (CREB) protein family of basic region
leucine zipper proteins, MSK1 (Mitogen and Stress activated protein Kinase), and heat
shock protein 27, HSP27,were analyzed [34,35]. Phosphorylation of ATF2 and HSP27 was
induced in response to ST362 (Fig 10A an Fig 10C). Levels were markedly increased
between 4 and 8 hours after ST362 treatment and therefore followed a similar time course of
activation as pP38 MAPK. There was no change in pMSK1 indicating that either p38
signaling is uncoupled from MSK1 activation or MDA-MB-231 cells already have a high
basal level of pMSK1. Importantly, pT581 MSK is also a target of ERK1/2, whose
phosphorylation was unchanged following SL treatment [36]. Another SL analogue, MEB55
was also able to induce phosphorylation of P38 ATF2 and HSP27 after 4 hours (Fig 10D
and Fig 10F). Significant cross talk exists between P38 and JNK1/2 and both modules share
subsets of MAPKKKs [37]. SL treatment also resulted in increased pJNK1/2 after 4 hours
(Fig 10D).
To determine if P38 was directly responsible for the SL induced phosphorylation of ATF2
and HSP27, cells were treated with a pharmacological P38 inhibitor, SB203580. SB203580
function was confirmed by immuno-blotting for pT334 MAPKAPK, a direct P38 target [38].
pT334 MAPKAPK phosphorylation was decreased in a dose dependent manner following
SB203580 exposure (Fig 10E). pT334 MAPKAPK was not increased upon MEB55
treatment, like pMSK1 (Fig 10A and Fig 10D), indicating that SLs treatment induces
activation of only specific subset of P38 targets. Treatment of cells with SB203580 at
concentrations of 2 μM and 10 μM was sufficient to inhibit HSP27 phosphorylation (Fig
10F) induced by ST362 and MEB55 but even 20 μM to 40 μM SB203580 did not inhibit
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ATF2 phosphorylation following SL treatment (Fig 10E) and instead resulted in a dose
independent increase in pATF2 levels. pP38 MAPK levels were also increased in SB203580
treated cells, a phenomenon also reported on the reagent datasheet (Cell Signaling
Technology, Danvers, MA) These results show that P38 is not responsible for ATF2
phosphorylation in this system. ATF2 can also be phosphorylated on T69 and T71 directly
by JNK1/2 and by Ras-ERK1/2 pathway [39]. Since ERK1/2 activation did not change upon
SL exposure (Fig 10A), JNK1/2 seems the likely candidate.
The PI3K/AKT pathway regulates a wide range of cellular functions including survival and
proliferation [40]. AKT activation requires phosphorylation of two critical residues, S473
near the carboxyl terminus which is considered a requirement for subsequent T308
phosphorylation and maximal AKT activation [41,42]. pT308 AKT levels decreased
dramatically between 4 and 8 hours in cell treated with MEB55 and remained low at 24
hours (Fig 11). Cells treated with the less potent SL analogue, EGO5, displayed a slight
delay in the inhibition of AKT phosphorylation, occurring between 8 and 24 hours. GSK3α/
β activity is inhibited by phophorylation on S9 [43]. pS9/21GSK3α/β did not correlate
closely with pAKT, however decreased pGSK3α/β was observed after 24 hours (Fig 10).
PDK1 phosphorylates AKT on T308 [41], which is itself activated by phosphorylation on
S241 [44]. Levels of pS241 PDK1 were reduced upon SL treatment and correlated closely
with reduced AKT phosphorylation observed in SL treated cells (Fig 11).
Discussion
Here we have presented data showing that synthetic strigolactone, GR24, and several SL
analogues possess inhibitory effects towards breast cancer cells lines growth and survival.
All six analogues induced a G2/M arrest with varying degrees of apoptosis in breast cancer
cells lines. Non-tumor ‘normal’ lines (MCF10A and BJ fibroblasts) displayed only limited
growth inhibition and only at the highest dose ranges tested, suggesting that tumorigenic
cells are more sensitive to the growth inhibitory effects of SLs and that SLs induce different
responses in cancer and normal cells. Furthermore SL inhibitory effects were not limited to
breast cancer cells and colon, lung and prostate cancer cells also exhibit increased sensitivity
to growth inhibition effects of SL analogues (data not shown). ST362 and MEB55 induced a
non-reversible reduction in cell viability after only 4 hours which correlated with
phosphorylation of p38 MAPK, JNK1/2 and inhibition of AKT. p38 and JNK1/2 are stress
activated MAPKs which play a crucial role in stress signaling cascade and are associated
with cell cycle arrest [45] and apoptosis in some cell systems [46,47]. p38 MAPK has been
reported to bind to and activate p53 and cause p53 induced apoptosis [48]. Although, SL
analogues were able to induce apoptosis in cells expressing both wild-type (MCF-7) and
mutant (MDA-MB-231, MDA-MB-436, T47D) p53, MCF7 cells were less sensitive.
Further experiments utilizing specific inhibitors are required to determine whether SL
induced apoptosis and cell cycle arrest is dependent on p38 or JNK1/2 activation. While
HSP27 phosphorylation was blocked by p38 pharmacological inhibitor, it did not block the
increase in ATF2 phosphorylation, which also could be activated by JNK1/2.
The differential response of cells to SL analogues (cytostatic versus cytotoxic) was dose
dependent but may also be determined by cell cycle stage. The IC50 doses for all five SLs
were 2-3 fold lower for MDA-MB-231 cells versus MCF-7 cells. This correlates with the
elevated proliferation rate of the MDA-MB-231 line (S-Phase fraction, 14-18% versus 2-4%
in MCF-7) and further supports a cancer therapeutic role for SLs based on their ability to
target rapidly dividing cells. A better understanding of the mechanisms of action is required
and may reveal ways to further sensitize cancer cells to the effects of these phytohormones.
Breast cancer cells grown as ‘stem-like cell enriched’ mammospheres exhibited an increased
sensitivity to SLs compared to cells grown in monolayer. SLs reduced mammosphere
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growth and induced mammosphere dissociation which correlated with their ability to
decrease viability. The similar effects of SLs analogues towards plant stem cells [17,18] may
indicate universal mechanisms of action.
In conclusion, this is the first study to assess the effects of strigolactones, a novel class of
phytohormones, on mammalian cells and particularly cancer cells. This work demonstrates
that SLs may represent a new class of anti-cancer therapeutic, able to target the bulk tumor
and also are effective at targeting ‘cancer stem-like cells’. The mechanism of action may
involve stress signaling activation and inhibition of survival signaling through inhibition of
AKT.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
SL Strigolactone
CSC Cancer stem cell
Ppm parts per million
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ERK Extracellular regulated kinase
P38 MAPK P38 Mitogen-activated protein kinase
MSK1 Mitogen- and stress-activated protein kinase
ATF2 Activating transcription factor 2
AKT Protein kinase B
IC Inhibitory concentration
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Effect of GR-24 on breast cancer cell line proliferation. MDA-MB-231, MDA-MB-436,
MCF-7 and BJ ‘normal’ fibroblasts were exposed to varying concentrations of GR-24 for up
to 10 days. At the indicated time points, plates were stained with crystal violet. Data are
reported as the Percent Absorbance (560nm) of vehicle control. Average ± standard
deviations (SD). Student's t-test (2-tailed, paired) was used to evaluate GR-24 treated groups
with vehicle (control) groups at final time point and regarded as being significant if p < 0.05
(*), very significant if p<0.01 (**), extremely significant if p<0.001 (***). (B) Graph
showing the light absorbance reading (560nm) after 7 days exposure to the indicated doses
of GR-24. Data expressed as a percentage of vehicle controls. Average of triplicate samples
± SD. Horizontal line (---) marks 50% reduction in Absorbance (560nm) relative to vehicle
controls. Right, Table showing inhibitory concentrations required for 50% reduction in
growth after 7days (IC50/72d), and calculated by performing linear regression with
interpolation between relevant y-axis data points (GraphPad Prism Software).
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: Effect of GR-24 on cell cycle progression. Cell Cycle Analysis of cell lines treated with the
SL analogue, GR-24 was carried out by propidium Iodide staining and Flow cytometry
analysis of total DNA content to evaluate the number of cells in different phases of the cell
cycle, including subG1 peak detection following Strigolactone treatment. Cells were treated
with the indicated doses of GR-24 for 48 hours. Data is representative of two independent
experiments.
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Mammosphere formation in the presence of GR-24. Images representative bright field
images of either primary mammospheres (A) or secondary mammospheres (B) or MDA-
MB-231 primary mammospheres (C) grown in the presence of the indicated doses of
GR-24, vehicle control or untreated (-). Magnification: 10× (A, B), 20× (C), scale bar
100uM. Bar graphs, showing the average number of mammospheres (over 100uM diameter)
per well of 96 well plate, visualized at 5× magnification. Data reported as average ±
standard deviations (SD) of triplicate wells and representative of at least two independent
experiments. Student's t-test (2-tailed, paired) was used to evaluate GR-24 treated groups
with vehicle (control) group and regarded as being significant if p < 0.05 (*), very
significant if p<0.01 (**), extremely significant if p<0.001 (***).
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Viability and ALDH expression following GR-24 treatment. (A) XTT viability assay on
MCF-7 secondary mammospheres treated with GR-24. GR-24 was added at the indicated
final concentrations. 5 days later, cell viability was determined (XTT kit, ATCC). Data
reported as % of vehicle control. Bars, Average ± standard deviations (SD) of triplicate
samples. Student's t-test (2-tailed, paired) was used to evaluate 5ppm treated group with
control group, p=0.0065 (**), (B) Analysis of ALDH1 expression in secondary MCF-7
mammospheres. Adherent MCF-7 cells and 8 days old secondary mammospheres were
prepared as single cells suspensions and ALDH expression was analyzed according to
manufacturer's instructions (Aldefluor kit, Stem Cell Technologies, Vancouver, CA). Right,
Bar graph showing the percentage of ALDH positive cells in either adherent MCF-7
cultures, primary (Adh), primary mammospheres grown in the presence of either 5ppm,
1ppm GR24 or vehicle (contrl) alone (0.6% Acetone) and 8 day old secondary
mammospheres (secondary). Secondary mammospheres exhibit an 2.4 fold enrichment for
ALDH activity. Primary mammospheres exhibit an small increase of 6% to 8% positivity for
ALDH expression. GR-24 treatment causes a reduction in ALDH expression from 6% to
2%.
Pollock et al. Page 17














Effect of Strigolactone analogues on human cancer cell line growth and viability. Cells were
seeded into 96 well plates in normal growing media. The following day media was replaced
with phenol free DMEM supplemented with 10% charcoal stripped serum and the indicated
doses of Strigolactone Analogue or vehicle (control) alone. Viability was assayed after 3
days (XTT, ATCC). Graphs are representative of two independent experiments with
duplicate replicate wells for each analysis.
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Cell Cycle Analysis of cancer cell lines treated with SL Analogues. Cells were treated for 48
hours with two different concentrations of SL analogue in phenol free- DMEM
supplemented with 10% charcoal stripped serum and Strigolactone at either IC50/72h or
∼IC50/72h+25% concentrations. (MCF-7 cells were IC50/72h >10ppm, so 20ppm
concentrations were used. Where IC50/72h=ND, concentrations were selected arbitrarily).
SL Analogues increase the percentage of cells in G2 phase in both MDA-MB-231 and
MCF-7 cells. MDA-MB-231 cells exhibit increased subG1/apoptotic fractions at higher
concentrations, as did ST357 in MCF-7 cells.
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Strigolactone analogues induce apoptosis in MDA-MB-231 cells (A) Hoechst33342 staining
of MDA-MB-231 cells treated with the indicatated doses of the Strigolacone analogue
ST362. Cells were treated with the indicated doses of SLs for 24 hours. Cells were fixed in
1% paraformaldehyde and stained with Hoechst33342. Magnification 200×. Scale bar,
50uM. Evidence of cell shrinkage, nuclear condensation and nuclear fragmentation is
observed, as well as eccentric nuclei, (insert). (B) XTT viability assay following SL
exposure. MDA-MB-231 cells were treated with the indicated concentrations of SL. After 2,
4 or 24 hours media was removed, cells were washed and media was replaced with growth
media minus SL. Cell viability was assessed at 24hrs. ST362 and MEB55 induce a non-
reversible reduction in cell viability in a dose-dependent and incubation time dependent
manner. Data are reported as % of vehicle control groups. Bars represent Average ±
standard deviations (SD). Statistical analysis, student's t-test (2-tailed, paired) versus vehicle
controls and regarded as being significant if p < 0.05 (*), p<0.01 (**), p<0.001 (***).
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Effect of SLs on MCF-7 mammosphere formation. MCF7 cells were seeded in MEBM
media into low attachment, 96 well plates in duplicate at 3000 cells per well. The same day
the indicated doses of Strigolactone analogues were added. After 7 days representative
images were taken (A), mammospheres numbers over 100uM diameter were counted (B).
Statistical analysis was done by two tail student t-test p≤0.05 (*), p≤0.005 (**), p≤0.001
(***).
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Effect of SLs on primary MCF-7 mammosphere integrity and viability. MCF7 cells were
seeded in MEBM media into low attachment, 96 well plates in duplicate at 3000 cells per
well and primary mammospheres left to grow for 7 days. At which time the indicated doses
of Strigolactone analogues were added to the media. (A) Representative images were taken
of mammospheres after 2 days of Strigolactone treatment. Dissociation is evident after 2
days exposure to SLs. Magnification 100×, Scale bar, 100uM. Insert, zoomed image. (B)
Mammospheres numbers (>100μM) following 5 days Strigolactone treatment. Statistical
Analysis, two tailed students t-test, p≤0.05 (*), p≤ 0.01 (**), p≤0.001 (***)
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SLs analogues induce stress response. Immunoblot analysis of MDA-MB-231 cells treated
with SL analogues. (A) immunoblot analysis of cells following treatment with ST362 at
either 10 or 5 ppm concentration or vehicle alone (-) for the indicated time points. (B) Bar
graph showing densitometric quantification of pP38 levels as shown in (A). (C) Immunoblot
analysis of cells treated with either vehicle or ST362 (10 ppm) for 1, 4,8 and 24 hrs.
Phosophorylation of HSP27 was analyzed. (D) MDA-MB-231 cells were treated with 10
ppm of the Strigolactone analogue, MEB55, or vehicle only for 4 hrs and then harvested and
analyzed by SDS-PAGE for protein expression. Levels of the indicated proteins are
depicted. (E) Immunoblot analysis of cells treated with ST362 alone or together with the
indicated concentrations of SB203580. (F) Immunoblot analysis of cells treated with
MEBB55 alone or together with SB203580. Cells were pretreated with SB203580 for 1hour
prior to addition of ST362 or MEB55. Cells were treated with ST362 or MEB55 alone or
together with SB203580 for 4 hours.
Pollock et al. Page 23














SLs analogues inhibit survival signaling. Immunoblot analysis of MDA-MB-231 cells
treated with either vehicle alone or with 10 ppm of either EGO5 or MEB55 for 1,4,8, 24hrs.
Whole cell extracts were prepared and analyzed for the expression of the indicated proteins.
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